{"id":71441,"date":"2026-05-20T11:35:00","date_gmt":"2026-05-20T11:35:00","guid":{"rendered":"https:\/\/medsbase.com\/hmg-peptide\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"hmg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/hmg-peptide\/","title":{"rendered":"HMG (Menopauz\u00e1ln\u00ed gonadotropin) \u2014 V\u00fdzkumn\u00e1 kvalita"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je HMG (v\u00fdzkumn\u00e9 kvality)?<\/h3>\n<p style=\"margin: 0;\"><strong>HMG<\/strong> (Lidsk\u00fd menopauz\u00e1ln\u00ed gonadotropin, tak\u00e9 zn\u00e1m\u00fd jako <strong>menotropin<\/strong>; CAS 61489-71-2) je mo\u010dov\u00fd glykoproteinov\u00fd hormon\u00e1ln\u00ed prepar\u00e1t obsahuj\u00edc\u00ed stejnou biologickou aktivitu LH a FSH (75 IU LH + 75 IU FSH per vial, standardn\u00ed pom\u011br 1:1). Purifikovan\u00fd z mo\u010di postmenopauz\u00e1ln\u00edch \u017een \u2014 jejich\u017e v\u00fddej hypofyz\u00e1rn\u00edch gonadotropin\u016f je p\u0159irozen\u011b zv\u00fd\u0161en absenc\u00ed negativn\u00ed zp\u011btn\u00e9 vazby \u2014 hMG je kanonick\u00fd <strong>du\u00e1ln\u00ed agonista LHCGR + FSHR<\/strong> v endokrinn\u00ed farmakologii a referen\u010dn\u00ed v\u00fdzkumn\u00fd n\u00e1stroj pro protokoly vy\u017eaduj\u00edc\u00ed simult\u00e1nn\u00ed steroidogenezi Leydigov\u00fdch bun\u011bk \/ theka bun\u011bk (LH strana) a aktivitu Sertoliho bun\u011bk \/ granul\u00f3zn\u00edch bun\u011bk (FSH strana). Dod\u00e1van\u00fd v\u00fdzkumn\u00fd materi\u00e1l je mo\u010dov\u011b extrahovan\u00fd glykoform s HPLC \u010distotou \u226599%. <em>Pouze pro laboratorn\u00ed v\u00fdzkum.<\/em> Odli\u0161n\u00e9 od klinick\u00fdch prepar\u00e1t\u016f menotropinu (Menopur, Menogon, Repronex).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd hMG mo\u010dov\u00e9ho p\u016fvodu s HPLC verifikac\u00ed \u226599% \u00b7 COA dostupn\u00fd na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 expedice v\u00fdzkumn\u00fdch materi\u00e1l\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>T\u0159\u00edda slou\u010denin<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Glykoproteinov\u00fd hormon\u00e1ln\u00ed prepar\u00e1t \u2014 fixn\u00ed sm\u011bs LH a FSH bioaktivity v pom\u011bru 1:1; du\u00e1ln\u00ed agonista LH\/CG-receptoru (LHCGR) + FSH-receptoru (FSHR); peptidov\u00fd hormon\u00e1ln\u00ed prepar\u00e1t<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Chemick\u00fd n\u00e1zev<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Hum\u00e1nn\u00ed menopauz\u00e1ln\u00ed gonadotropin (Menotropin; mo\u010dov\u011b extrahovan\u00fd prepar\u00e1t; synonyma: hMG, urofollitropin-s-LH, menopauz\u00e1ln\u00ed gonadotropin)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS \u010d\u00edslo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">61489-71-2 (menotropin \/ hMG sm\u00ed\u0161en\u00fd prepar\u00e1t)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Aktivn\u00ed slo\u017eky<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>LH<\/strong> (luteiniza\u010dn\u00ed hormon, ~30 kDa heterodimer; \u03b1 92 aa + \u03b2 121 aa, glykosylovan\u00fd) \u2014 75 IU per vial; <strong>FSH<\/strong> (folikuly stimuluj\u00edc\u00ed hormon, ~30 kDa heterodimer; \u03b1 92 aa + \u03b2 111 aa, glykosylovan\u00fd) \u2014 75 IU per vial. \u03b1-podjednotka je spole\u010dn\u00e1 pro LH, FSH, HCG a TSH; \u03b2-podjednotky zaji\u0161\u0165uj\u00ed receptorovou specifitu. Oba gonadotropiny jsou rozs\u00e1hle N- a O-glykosylov\u00e1ny.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pom\u011br biologick\u00e9 aktivity<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">LH:FSH aktivita = 1:1 (standardn\u00ed pom\u011br hMG od standardizace \u00fa\u010dinnosti v pozdn\u00edch 90. letech; ob\u011b aktivity m\u011b\u0159eny WHO bioanal\u00fdzou proti mezin\u00e1rodn\u00edm referen\u010dn\u00edm standard\u016fm)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>HCG ko-purifikace (v\u00fdzkumn\u011b relevantn\u00ed)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Charakteristika mo\u010dov\u011b derivovan\u00fdch p\u0159\u00edpravk\u016f hMG: publikovan\u00e9 anal\u00fdzy slo\u017een\u00ed uv\u00e1d\u011bj\u00ed, \u017ee p\u0159ibli\u017en\u011b <strong>95% in-vivo LH-receptorov\u00e9 bioaktivity je p\u0159isuzov\u00e1no stopov\u00e9mu mno\u017estv\u00ed HCG ko-purifikovan\u00e9ho z postmenopauz\u00e1ln\u00ed mo\u010di<\/strong> (Wolfenson et al. 2005 a dal\u0161\u00ed). HCG a LH se v\u00e1\u017eou na stejn\u00fd LHCGR s podobnou afinitou, ale HCG m\u00e1 polo\u010das 33\u201337 h oproti ~20 min u LH \u2014 tak\u017ee i mal\u00e1 mno\u017estv\u00ed HCG dominuj\u00ed in-vivo LH-ekvivalentn\u00edmu sign\u00e1lu. V\u00fdzkumn\u00edci by si toho m\u011bli b\u00fdt v\u011bdomi p\u0159i porovn\u00e1v\u00e1n\u00ed hMG s \u010dist\u00fdmi rekombinantn\u00edmi LH (Luveris) p\u0159\u00edpravky.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanismus \u00fa\u010dinku<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Dualn\u00ed agonismus GPCR. <strong>LHCGR<\/strong> (Gs-v\u00e1zan\u00fd, Leydigovy \/ theka \/ granul\u00f3zn\u00ed \/ bu\u0148ky corpus luteum) \u2192 kask\u00e1da cAMP-PKA-StAR-CYP17A1 \u2192 biosynt\u00e9za androgen\u016f. <strong>FSHR<\/strong> (Gs-v\u00e1zan\u00fd, Sertoliho bu\u0148ky u mu\u017e\u016f \/ granul\u00f3zn\u00ed bu\u0148ky u \u017een) \u2192 kask\u00e1da cAMP-PKA-CYP19A1\/aromat\u00e1za \u2192 podpora spermatogeneze (mu\u017ei) nebo konverze androgen\u016f na estrogeny + folikul\u00e1rn\u00ed zr\u00e1n\u00ed (\u017eeny). Dualn\u00ed aktivace je to, co odli\u0161uje hMG od \u010dist\u00fdch LH (Luveris \/ rLH) nebo \u010dist\u00fdch FSH (Gonal-F \/ Puregon \/ rFSH) p\u0159\u00edpravk\u016f.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sm\u00ed\u0161en\u00e1 p\u0159\u00edprava \u2014 jak LH, tak FSH jsou heterodimern\u00ed glykoproteiny. \u03b1-podjednotka (sd\u00edlen\u00e1) ~92 aa, identick\u00e1 u LH\/FSH\/HCG\/TSH. \u03b2-podjednotka LH ~121 aa, \u03b2-podjednotka FSH ~111 aa. \u00dapln\u00e9 sekvence dostupn\u00e9 z UniProt: LH\u03b2 (P01229), FSH\u03b2 (P01225), GPH\u03b1 (P01215).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item2<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sm\u00ed\u0161en\u00e1 p\u0159\u00edprava glykoprotein\u016f extrahovan\u00fdch z mo\u010di \u2014 FSH (\u03b1 92aa + \u03b2 111aa) + LH (\u03b1 92aa + \u03b2 121aa) heterodimery v pom\u011bru biologick\u00e9 aktivity ~1:1. \u017d\u00e1dn\u00fd jednotn\u00fd molekul\u00e1rn\u00ed vzorec kv\u016fli heterogenn\u00edmu glykosyla\u010dn\u00edmu vzoru v p\u0159\u00edpravku.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Plazmatick\u00fd polo\u010das<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Aktivita FSH: termin\u00e1ln\u00ed polo\u010das ~30\u201340 h (\u0159\u00edzeno sialylac\u00ed, podobn\u011b jako u jin\u00fdch glykoproteinov\u00fdch hormon\u016f). Aktivita LH v hMG: nomin\u00e1ln\u011b ~10\u201320 h (ale v praxi je ovlivn\u011bna ko-purifikovanou frakc\u00ed HCG s polo\u010dasem 33\u201337 h \u2014 viz v\u00fd\u0161e uveden\u00e1 pozn\u00e1mka o ko-purifikaci HCG).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item11<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd amorfn\u00ed pr\u00e1\u0161ek s manitolem nebo lakt\u00f3zou jako stabiliza\u010dn\u00ed matric\u00ed; jednor\u00e1zov\u00e9 v\u00fdzkumn\u00e9 lahvi\u010dky<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item13<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (ov\u011b\u0159eno HPLC); WHO biotest potvrzuje aktivitu LH a FSH p\u0159i deklarovan\u00fdch 75 IU ka\u017ed\u00e9ho. Certifik\u00e1t anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rozpustnost<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Rekonstituovat v bakteriostatick\u00e9 vod\u011b v objemu 1,0 mL na lahvi\u010dku \u2192 75 IU LH + 75 IU FSH na mL pracovn\u00edho roztoku; jin\u00e9 \u0159ed\u011bn\u00ed dle protokolu. Lyofiliz\u00e1t se rychle rozpou\u0161t\u00ed p\u0159i jemn\u00e9m krou\u017een\u00ed. <strong>Net\u0159epat; nepou\u017e\u00edvat vortex<\/strong> \u2014 vysokosmykov\u00e9 m\u00edch\u00e1n\u00ed zp\u016fsobuje disociaci \u03b1\/\u03b2 heterodimer\u016f obou slo\u017eek LH a FSH.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd: 2\u20138 \u00b0C neotev\u0159en\u00fd pro kr\u00e1tkodob\u00e9 skladov\u00e1n\u00ed pracovn\u00edho roztoku; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed (stabilita \u226536 m\u011bs\u00edc\u016f p\u0159i \u221220 \u00b0C; \u226518 m\u011bs\u00edc\u016f p\u0159i 2\u20138 \u00b0C). Rekonstituovan\u00fd: 2\u20138 \u00b0C, pou\u017e\u00edt do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. <strong>Nezamrazujte rekonstituovan\u00fd materi\u00e1l.<\/strong> \u2014 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed zp\u016fsobuj\u00ed disociaci LH a FSH \u03b1\/\u03b2 heterodimer\u016f a ni\u010d\u00ed biologickou aktivitu.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at. hMG \/ menotropin je na Seznamu zak\u00e1zan\u00fdch l\u00e1tek Sv\u011btov\u00e9 antidopingov\u00e9 agentury (WADA) (t\u0159\u00edda S2, Peptidov\u00e9 hormony, r\u016fstov\u00e9 faktory a p\u0159\u00edbuzn\u00e9 l\u00e1tky) a je zak\u00e1z\u00e1n kdykoli u mu\u017esk\u00fdch sportovc\u016f. V\u00fdzkumn\u00edci pracuj\u00edc\u00ed s lidsk\u00fdmi subjekty by si m\u011bli b\u00fdt v\u011bdomi tohoto regula\u010dn\u00edho statusu.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Co je HMG (Menotropin)?<\/h2>\n<p><strong>HMG<\/strong> \u2014 Lidsk\u00fd menopauz\u00e1ln\u00ed gonadotropin, tak\u00e9 zn\u00e1m\u00fd jako <strong>menotropin<\/strong> (CAS 61489-71-2) \u2014 je glykoproteinov\u00fd hormon\u00e1ln\u00ed p\u0159\u00edpravek z\u00edskan\u00fd z mo\u010di, obsahuj\u00edc\u00ed stejn\u00e9 mno\u017estv\u00ed biologick\u00e9 aktivity LH (luteiniza\u010dn\u00edho hormonu) a FSH (folikuly stimuluj\u00edc\u00edho hormonu), standardizovan\u00fd na 75 IU ka\u017ed\u00e9ho z nich v jedn\u00e9 lahvi\u010dce. Je purifikov\u00e1n iontovou v\u00fdm\u011bnou a gelovou filtra\u010dn\u00ed chromatografi\u00ed z mo\u010di postmenopauz\u00e1ln\u00edch \u017een, kter\u00e9 maj\u00ed p\u0159irozen\u011b zv\u00fd\u0161en\u00fd v\u00fddej hypofyz\u00e1rn\u00edch gonadotropin\u016f (LH a FSH typicky 50\u2013100+ mIU\/ml ka\u017ed\u00fd) v d\u016fsledku ztr\u00e1ty ovari\u00e1ln\u00ed negativn\u00ed zp\u011btn\u00e9 vazby, kter\u00e1 doprov\u00e1z\u00ed menopauzu.<\/p>\n<p>\u201cMenopauz\u00e1ln\u00ed\u201d v n\u00e1zvu odkazuje na tento zdroj: mo\u010d postmenopauz\u00e1ln\u00edch \u017een je nejkoncentrovan\u011bj\u0161\u00edm p\u0159\u00edrodn\u00edm zdrojem LH a FSH dostupn\u00fdm pro pr\u016fmyslov\u00e9 \u010di\u0161t\u011bn\u00ed a hMG se z tohoto zdroje vyr\u00e1b\u00ed od po\u010d\u00e1tku 60. let (p\u016fvodn\u00ed p\u0159\u00edpravek Pergonal vyvinut\u00fd Cesare Serono). Slo\u017een\u00ed hMG se v pr\u016fb\u011bhu desetilet\u00ed v\u00fdrazn\u011b zdokonalilo \u2014 d\u0159\u00edv\u011bj\u0161\u00ed p\u0159\u00edpravky m\u011bly vysoce variabiln\u00ed pom\u011br LH:FSH a v\u00fdznamn\u00e9 mno\u017estv\u00ed proteinov\u00fdch ne\u010distot; modern\u00ed p\u0159\u00edpravky (z\u00e1klad na\u0161eho v\u00fdzkumn\u00e9ho materi\u00e1lu) jsou standardizov\u00e1ny na 75:75 IU biologick\u00e9 aktivity na lahvi\u010dku s \u010distotou \u226599 % HPLC.<\/p>\n<p>hMG je kanonick\u00fd n\u00e1stroj pro farmakologii dvojit\u00fdch gonadotropin\u016f. Zat\u00edmco HCG selektivn\u011b aktivuje LHCGR, zat\u00edmco \u010dist\u00e9 LH (rekombinantn\u00ed Luveris) selektivn\u011b aktivuje LHCGR s fyziologick\u00fdm polo\u010dasem, zat\u00edmco \u010dist\u00e9 FSH (rekombinantn\u00ed Gonal-F \/ Puregon) selektivn\u011b aktivuje FSHR, hMG aktivuje oba receptory sou\u010dasn\u011b v pevn\u00e9m pom\u011bru 1:1. Tyto dva receptory jsou exprimov\u00e1ny na r\u016fzn\u00fdch populac\u00edch bun\u011bk v gon\u00e1d\u00e1ch \u2014 LHCGR na Leydigov\u00fdch bu\u0148k\u00e1ch \/ thek\u00e1ln\u00edch bu\u0148k\u00e1ch \/ luteinizovan\u00fdch granul\u00f3zn\u00edch bu\u0148k\u00e1ch \/ corpus luteum; FSHR na Sertoliho bu\u0148k\u00e1ch \/ mur\u00e1ln\u00edch granul\u00f3zn\u00edch bu\u0148k\u00e1ch \u2014 tak\u017ee dvojit\u00e1 aktivace vytv\u00e1\u0159\u00ed \u00fapln\u00fd fyziologick\u00fd gonadotropn\u00ed stimul, kter\u00fd v\u00edce napodobuje endogenn\u00ed v\u00fddej hypof\u00fdzy v polovin\u011b cyklu ne\u017e aktivace ka\u017ed\u00e9ho receptoru samostatn\u011b.<\/p>\n<p><strong>V\u00fdzkumn\u00e1 nuance: kopurifikace HCG.<\/strong> Publikovan\u00e9 anal\u00fdzy slo\u017een\u00ed hMG p\u0159\u00edpravk\u016f z\u00edskan\u00fdch z mo\u010di uv\u00e1d\u011bj\u00ed, \u017ee v\u011bt\u0161ina in-vivo bioaktivity LH receptoru je ve skute\u010dnosti zp\u016fsobena stopov\u00fdm mno\u017estv\u00edm HCG kopurifikovan\u00e9ho z postmenopauz\u00e1ln\u00ed mo\u010di \u2014 podle n\u011bkter\u00fdch anal\u00fdz p\u0159ibli\u017en\u011b 95 % bioaktivity zprost\u0159edkovan\u00e9 LH receptorem (Wolfenson et al., 2005). Je to proto, \u017ee HCG a LH se v\u00e1\u017eou na stejn\u00fd LHCGR s podobnou afinitou, ale HCG m\u00e1 polo\u010das v plazm\u011b 33\u201337 h oproti ~20 minut\u00e1m u LH, tak\u017ee i mal\u00e1 mno\u017estv\u00ed HCG dominuj\u00ed kumulativn\u00edmu in-vivo sign\u00e1lu ekvivalentn\u00edmu LH. To je \u010d\u00e1ste\u010dn\u011b d\u016fvod, pro\u010d hMG zp\u016fsobuje trvalou stimulaci Leydigov\u00fdch bun\u011bk, p\u0159esto\u017ee nomin\u00e1ln\u00ed \u201cLH aktivita\u201d samotn\u00e9ho LH je kr\u00e1tkodob\u00e1. Pro v\u00fdzkumn\u00e9 protokoly, kde tento rozd\u00edl z\u00e1le\u017e\u00ed (farmakologie \u010dist\u00e9ho LH vs. sm\u00ed\u0161en\u00fd LH sign\u00e1l kontaminovan\u00fd HCG), je rekombinantn\u00ed LH (Luveris) \u010dist\u0161\u00edm n\u00e1strojem; pro protokoly, kde je c\u00edlem dvojit\u00e1 aktivace LHCGR + FSHR ve fyziologick\u00e9m pom\u011bru 1:1, je hMG kanonickou referenc\u00ed.<\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 dvojit\u00e1 aktivace LHCGR + FSHR<\/h2>\n<p>Mechanismus hMG je dvojit\u00fdm sou\u010dtem jeho dvou slo\u017ekov\u00fdch aktivit, ob\u011b jsou dob\u0159e charakterizov\u00e1ny v endokrinn\u00ed farmakologii:<\/p>\n<ul>\n<li><strong>LH (a kopurifikovan\u00e9 HCG) \u2192 aktivace LHCGR<\/strong> \u2014 LH slo\u017eka (a stopov\u00e9 HCG kopurifikovan\u00e9 z postmenopauz\u00e1ln\u00ed mo\u010di) se v\u00e1\u017ee na LH\/CG receptor na Leydigov\u00fdch bu\u0148k\u00e1ch (varle) a thek\u00e1ln\u00edch \/ granul\u00f3zn\u00edch \/ lute\u00e1ln\u00edch bu\u0148k\u00e1ch (vaje\u010dn\u00edk). Gs-vazba zvy\u0161uje cAMP, aktivuje PKA, upreguluje StAR-zprost\u0159edkovan\u00fd transport cholesterolu do mitochondri\u00ed a indukuje steroidogenn\u00ed enzymy CYP11A1 \/ CYP17A1 \/ 3\u03b2-HSD \/ 17\u03b2-HSD \u2014 co\u017e vede k de-novo biosynt\u00e9ze testosteronu (mu\u017ei) nebo androstendionu (\u017eeny).<\/li>\n<li><strong>FSH \u2192 aktivace FSHR<\/strong> \u2014 Komponenta FSH se v\u00e1\u017ee na receptor FSH na Sertoliho bu\u0148k\u00e1ch (varlata) a mural granul\u00f3zn\u00edch bu\u0148k\u00e1ch (vaje\u010dn\u00edk). FSHR je tak\u00e9 sp\u0159a\u017een s Gs, ale jeho n\u00e1sledn\u00fd program je odli\u0161n\u00fd: v Sertoliho bu\u0148k\u00e1ch aktivace FSHR spou\u0161t\u00ed androgen-v\u00e1zaj\u00edc\u00ed protein (ABP), inhibin B a struktur\u00e1ln\u00ed podp\u016frn\u00fd program, kter\u00fd udr\u017euje spermatogenezi; v granul\u00f3zn\u00edch bu\u0148k\u00e1ch aktivace FSHR spou\u0161t\u00ed CYP19A1 (aromat\u00e1zu), kter\u00e1 p\u0159em\u011b\u0148uje androgeny poch\u00e1zej\u00edc\u00ed z thek\u00e1ln\u00edch bun\u011bk na estrogeny, a podporuje folikul\u00e1rn\u00ed zr\u00e1n\u00ed p\u0159es ant\u00e1ln\u00ed a preovula\u010dn\u00ed stadia.<\/li>\n<li><strong>Kombinovan\u00fd model dvou bun\u011bk a dvou gonadotropin\u016f<\/strong> \u2014 Klasick\u00fd endokrinn\u00ed r\u00e1mec. V mu\u017esk\u00fdch varlatech LH-stimulovan\u00e9 Leydigovy bu\u0148ky produkuj\u00ed testosteron, kter\u00fd difunduje do p\u0159ilehl\u00fdch Sertoliho bun\u011bk, kde FSH-indukovan\u00fd androgen-v\u00e1zaj\u00edc\u00ed protein a metabolick\u00fd apar\u00e1t Sertoliho bun\u011bk p\u0159em\u011b\u0148uj\u00ed testosteron na mikroprost\u0159ed\u00ed s vysokou intratestikul\u00e1rn\u00ed koncentrac\u00ed testosteronu, kter\u00e9 je nezbytn\u00e9 pro spermatogenezi. V \u017eensk\u00e9m vaje\u010dn\u00edku LH-stimulovan\u00e9 thek\u00e1ln\u00ed bu\u0148ky produkuj\u00ed androgeny, kter\u00e9 difunduj\u00ed do p\u0159ilehl\u00fdch granul\u00f3zn\u00edch bun\u011bk, kde FSH-indukovan\u00e1 aromat\u00e1za p\u0159em\u011b\u0148uje androgeny na estrogeny. Model dvou bun\u011bk a dvou gonadotropin\u016f je kanonick\u00fdm r\u00e1mcem a hMG je kanonick\u00fdm farmakologick\u00fdm n\u00e1strojem pro sou\u010dasn\u00e9 zapojen\u00ed obou jeho polovin.<\/li>\n<li><strong>Desenzibilizace receptor\u016f a tachyfylaxe<\/strong> \u2014 Jak LHCGR, tak FSHR podl\u00e9haj\u00ed arrestin-zprost\u0159edkovan\u00e9 desenzibilizaci po dlouhodob\u00e9 expozici agonisty. Opakovan\u00e9 vysok\u00e9 d\u00e1vky hMG mohou v\u00e9st k downregulaci receptor\u016f \u2014 dob\u0159e zdokumentovan\u00fd jev v publikovan\u00e9m v\u00fdzkumu farmakologie gonadotropin\u016f relevantn\u00ed pro chronick\u00e9 d\u00e1vkovac\u00ed protokoly.<\/li>\n<li><strong>Hypotalamo-hypofyz\u00e1rn\u00ed zp\u011btn\u00e1 vazba<\/strong> \u2014 Stejn\u011b jako u HCG, gon\u00e1d\u00e1ln\u00ed steroidn\u00ed v\u00fdstup vyvolan\u00fd hMG se vrac\u00ed do hypotalamu a hypof\u00fdzy, aby potla\u010dil endogenn\u00ed sekreci GnRH a LH\/FSH. V kontextu v\u00fdzkumu suprese HPG (n\u00e1hrada testosteronu, expozice AAS, farmakologick\u00e1 antagonizace GnRH), hMG obch\u00e1z\u00ed hypotalamo-hypofyz\u00e1rn\u00ed blok\u00e1du p\u016fsoben\u00edm p\u0159\u00edmo na gon\u00e1d\u00e1ln\u00ed receptory \u2014 zachov\u00e1v\u00e1 sou\u010dasn\u011b jak funkci Leydigov\u00fdch bun\u011bk (LH strana), tak podp\u016frnou funkci Sertoliho bun\u011bk \/ spermatogeneze (FSH strana), co\u017e odli\u0161uje hMG od \u010dist\u011b HCG protokol\u016f v tomto v\u00fdzkumn\u00e9m kontextu.<\/li>\n<\/ul>\n<p>Farmakokinetick\u00fd profil hMG v z\u00e1sad\u011b odpov\u00edd\u00e1 jeho komponent\u00e1m: aktivita FSH p\u0159etrv\u00e1v\u00e1 s termin\u00e1ln\u00edm polo\u010dasem 30\u201340 h, aktivita ekvivalentn\u00ed LH je dominov\u00e1na dlouh\u00fdm polo\u010dasem ko-purifikovan\u00e9ho HCG (33\u201337 h) a kombinovan\u00e1 p\u0159\u00edprava vytv\u00e1\u0159\u00ed trvalou dvojitou stimulaci gonadotropin\u016f na d\u00e1vku po dobu 24\u201372 h. Typick\u00e9 d\u00e1vkov\u00e1n\u00ed ve v\u00fdzkumn\u00fdch protokolech je 75\u2013225 IU SC denn\u011b ve v\u00fdzkumu na hlodavc\u00edch nebo lidsk\u00fdch subjektech \u2014 ekvivalent 1\u20133 lahvi\u010dk\u00e1m s\u00edly 75 IU.<\/p>\n<h2>Publikovan\u00e9 v\u00fdzkumn\u00e9 aplikace<\/h2>\n<p>hMG se pou\u017e\u00edv\u00e1 v laboratorn\u00edch v\u00fdzkumn\u00fdch kontextech, kter\u00e9 zkoumaj\u00ed:<\/p>\n<ul>\n<li><strong>Farmakologii gonadotropin\u016f \u2014 kanonick\u00e1 dvojit\u00e1 receptorov\u00e1 reference<\/strong> \u2014 nej\u010dast\u011bji citovan\u00fd agonista LHCGR + FSHR v publikovan\u00e9m v\u00fdzkumu gonadotropin\u016f; standardn\u00ed referen\u010dn\u00ed slou\u010denina pro rozli\u0161en\u00ed signalizace pouze LH vs pouze FSH vs kombinovan\u00e9 gonadotropinov\u00e9 signalizace<\/li>\n<li><strong>V\u00fdzkum indukce spermatogeneze<\/strong> \u2014 v modelech hypogonadotropn\u00edho hypogonadismu u hlodavc\u016f je hMG (s nebo bez dopl\u0148kov\u00e9ho HCG) kanonick\u00fdm n\u00e1strojem pro indukci spermatogeneze obnoven\u00edm jak produkce testosteronu Leydigov\u00fdmi bu\u0148kami, tak podpory FSH Sertoliho bu\u0148kami; standardn\u00ed v\u00fdzkumn\u00fd protokolov\u00fd cyklus je 75\u2013150 IU SC t\u0159ikr\u00e1t t\u00fddn\u011b po dobu 6\u201324 m\u011bs\u00edc\u016f v klinicko-transla\u010dn\u00edm v\u00fdzkumu<\/li>\n<li><strong>V\u00fdzkum stimulace vaje\u010dn\u00edk\u016f u \u017een<\/strong> \u2014 historick\u00fd z\u00e1kladn\u00ed n\u00e1stroj v\u00fdzkumu in-vitro fertilizace; hMG podporuje v\u00fdvoj folikul\u016f p\u0159es ant\u00e1ln\u00ed a preovula\u010dn\u00ed stadia v publikovan\u00fdch protokolech indukce ovulace, typicky kombinovan\u00fdch s HCG jako spou\u0161t\u011b\u010dem ovulace; \u0161iroce pou\u017e\u00edv\u00e1n ve v\u00fdzkumu syndromu polycystick\u00fdch ovari\u00ed (PCOS), nevysv\u011btlen\u00e9 neplodnosti a asistovan\u00fdch reproduk\u010dn\u00edch technologi\u00ed<\/li>\n<li><strong>V\u00fdzkum dvoubun\u011b\u010dn\u00e9ho dvougonadotropinov\u00e9ho modelu<\/strong> \u2014 kanonick\u00fd r\u00e1mec farmakologie gon\u00e1d\u00e1ln\u00ed steroidogeneze; hMG je standardn\u00ed n\u00e1stroj pro sou\u010dasnou aktivaci obou \u010d\u00e1st\u00ed modelu; publikovan\u00fd v\u00fdzkum kokultur Sertoliho-Leydigov\u00fdch bun\u011bk a theka-granul\u00f3zn\u00edch bun\u011bk vyu\u017e\u00edv\u00e1 hMG k replikaci fyziologick\u00e9ho dvojit\u00e9ho receptorov\u00e9ho stimulu<\/li>\n<li><strong>V\u00fdzkum suprese a obnovy HPG osy<\/strong> \u2014 v publikovan\u00fdch v\u00fdzkumn\u00fdch modelech, kde byla endogenn\u00ed LH\/FSH potla\u010dena (exogenn\u00edm testosteronem, expozic\u00ed AAS nebo GnRH antagonismem), hMG zachov\u00e1v\u00e1 funkci Leydigov\u00fdch bun\u011bk i Sertoliho bun\u011bk p\u0159\u00edmou aktivac\u00ed gon\u00e1d\u00e1ln\u00edch receptor\u016f \u2014 co\u017e jej odli\u0161uje od protokol\u016f s pouh\u00fdm HCG, kter\u00e9 zachov\u00e1vaj\u00ed pouze funkci LH strany a riskuj\u00ed atrofii Sertoliho bun\u011bk<\/li>\n<li><strong>Srovn\u00e1vac\u00ed farmakologie vs \u010dist\u00e1 LH \/ \u010dist\u00e1 FSH \/ HCG<\/strong> \u2014 publikovan\u00e9 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed hMG vs rekombinantn\u00ed LH (Luveris), rekombinantn\u00ed FSH (Gonal-F \/ Puregon), rekombinantn\u00ed HCG (Ovidrel) a r\u016fzn\u00fdch kombinac\u00ed je rozs\u00e1hl\u00e9; hMG je mo\u010dov\u011b derivovan\u00fd 1:1 sm\u00ed\u0161en\u00fd referen\u010dn\u00ed standard, v\u016f\u010di kter\u00e9mu jsou v\u0161echny tyto l\u00e1tky porovn\u00e1v\u00e1ny<\/li>\n<li><strong>V\u00fdvoj folikul\u016f a biologie granul\u00f3zn\u00edch bun\u011bk<\/strong> \u2014 publikovan\u00fd v\u00fdzkum ex-vivo folikul\u00e1rn\u00edch kultur a prim\u00e1rn\u00edch granul\u00f3zn\u00edch bun\u011bk vyu\u017e\u00edv\u00e1 hMG k sou\u010dasn\u00e9mu \u0159\u00edzen\u00ed produkce androgen\u016f theka bu\u0148kami a indukci aromat\u00e1zy granul\u00f3zn\u00edmi bu\u0148kami \u2014 nejfyziologi\u010dt\u011bj\u0161\u00ed dostupn\u00fd in-vitro stimul<\/li>\n<li><strong>Biologie corpus luteum<\/strong> \u2014 trval\u00e1 aktivace LHCGR LH slo\u017ekou (a spole\u010dnou purifikovanou HCG) udr\u017euje funkci corpus luteum a produkci progesteronu; pou\u017e\u00edv\u00e1 se ve v\u00fdzkumu lute\u00e1ln\u00ed f\u00e1ze a luteo-placent\u00e1rn\u00edho p\u0159echodu<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext t\u00fdkaj\u00edc\u00ed se peptid\u016f v\u00fdzkumu HPG osy a reproduk\u010dn\u00edho syst\u00e9mu v tomto katalogu viz <a href=\"https:\/\/medsbase.com\/cs\/hcg-peptide\/\">HCG (lidsk\u00fd choriov\u00fd gonadotropin)<\/a> (\u010dist\u00fd agonista LHCGR \u2014 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed; pouze aktivita LH strany), <a href=\"https:\/\/medsbase.com\/cs\/kisspeptin-10\/\">Kisspeptin-10<\/a> (upstreamov\u00fd agonista hypothalamick\u00e9ho Kiss1R \u2014 \u0159\u00edd\u00ed endogenn\u00ed pulzaci GnRH), <a href=\"https:\/\/medsbase.com\/cs\/pt-141\/\">PT-141 (Bremelanotid)<\/a> (farmakologie melanokortinov\u00fdch receptor\u016f \u2014 v\u00fdzkum sexu\u00e1ln\u00edch funkc\u00ed), a <a href=\"https:\/\/medsbase.com\/cs\/oxytocin-acetate\/\">Oxytocin Acetate<\/a> (zadn\u00ed hypofyz\u00e1rn\u00ed peptidov\u00fd hormon). Prohl\u00e9dn\u011bte si cel\u00fd <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\">katalog v\u00fdzkumn\u00fdch peptid\u016f a slou\u010denin<\/a>.<\/p>\n<h2>Dostupn\u00e9 s\u00edly a koncentrace<\/h2>\n<p>MedsBase nab\u00edz\u00ed HMG (urin\u00e1rn\u011b extrahovan\u00fd menotropin) v jedn\u00e9 lyofilizovan\u00e9 d\u00e1vce kalibrovan\u00e9 na standardn\u00ed bioaktivn\u00ed jednotku 1:1 LH:FSH. Vial je k dispozici v balen\u00ed po 10 nebo 20 vialech:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">S\u00edla vialky<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typick\u00fd v\u00fdzkumn\u00fd p\u0159\u00edpad u\u017eit\u00ed<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>75 IU LH + 75 IU FSH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standardn\u00ed v\u00fdzkumn\u00e1 d\u00e1vka (mezin\u00e1rodn\u00ed referen\u010dn\u00ed jednotka) \u2014 jednor\u00e1zov\u00e1 dvojit\u00e1 stimulace gonadotropiny, protokoly indukce spermatogeneze (75\u2013225 IU SC t\u0159ikr\u00e1t t\u00fddn\u011b), v\u00fdzkum ovari\u00e1ln\u00ed stimulace, dvoubun\u011b\u010dn\u00e1 kultura se stimulac\u00ed dvou gonadotropin\u016f, srovn\u00e1vac\u00ed farmakologie vs rekombinantn\u00ed \u010dist\u00e9-LH a \u010dist\u00e9-FSH prepar\u00e1ty<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Vial 75:75 IU je mezin\u00e1rodn\u00ed referen\u010dn\u00ed d\u00e1vkov\u00e1 jednotka a form\u00e1t pou\u017e\u00edvan\u00fd prakticky ve v\u0161ech publikovan\u00fdch v\u00fdzkumech gonadotropin\u016f a klinick\u00e9 praxi. V\u00edcevialov\u00e9 d\u00e1vkov\u00e1n\u00ed (150 IU, 225 IU na pod\u00e1n\u00ed) je standardem pro protokoly s vy\u0161\u0161\u00edmi d\u00e1vkami. Balen\u00ed po 20 vialech je ekonomi\u010dt\u011bj\u0161\u00ed n\u00e1kup na IU pro protokoly s prodlou\u017een\u00fdm cyklem nebo v\u00edce kohortami.<\/p>\n<h2>Jak se porovn\u00e1v\u00e1 \u2014 HMG vs HCG<\/h2>\n<p><a href=\"https:\/\/medsbase.com\/cs\/hcg-peptide\/\">HCG<\/a> a hMG jsou dva urin\u00e1rn\u011b derivovan\u00e9 gonadotropinov\u00e9 prepar\u00e1ty v tomto katalogu, kter\u00e9 c\u00edl\u00ed na gonadotropinov\u00fd receptorov\u00fd syst\u00e9m mechanicky odli\u0161n\u00fdmi zp\u016fsoby. HCG je <em>\u010dist\u00fd<\/em> agonista receptoru LH\/CG \u2014 pouze aktivace Leydigov\u00fdch bun\u011bk \/ theka bun\u011bk. hMG je <em>du\u00e1ln\u00ed<\/em> P\u0159\u00edpravek LH + FSH \u2014 sou\u010dasn\u011b aktivuje ob\u011b \u010d\u00e1sti dvoubun\u011b\u010dn\u00e9ho dvougonadotropn\u00edho modelu. Volba mezi nimi ve v\u00fdzkumu z\u00e1vis\u00ed na tom, zda protokol vy\u017eaduje pouze aktivaci LH strany nebo kombinovanou aktivaci LH strany + FSH strany.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HMG (Menotropin)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HCG<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Slo\u017een\u00ed<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pevn\u00fd pom\u011br 1:1: LH 75 IU + FSH 75 IU na lahvi\u010dku (+ stopov\u00e9 mno\u017estv\u00ed HCG, kter\u00e9 dominuje LH-ekvivalentn\u00edmu in-vivo sign\u00e1lu)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u010cist\u00e9 HCG (mo\u010dov\u00e9ho p\u016fvodu) \u2014 jedin\u00fd glykoprotein<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Aktivovan\u00e9 receptory<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR <em>a<\/em> FSHR \u2014 dvojit\u00e1 aktivace gonadotropn\u00edch receptor\u016f<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pouze LHCGR \u2014 jedin\u00fd receptor<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Zdroj<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mo\u010d postmenopauz\u00e1ln\u00edch \u017een<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mo\u010d t\u011bhotn\u00fdch \u017een (uHCG) nebo rekombinantn\u00ed CHO bu\u0148ky (rHCG)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Nejlep\u0161\u00ed v\u00fdzkumn\u00e9 aplikace<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indukce spermatogeneze (zachov\u00e1v\u00e1 funkci Sertoliho bun\u011bk), stimulace ovari\u00e1ln\u00edch folikul\u016f, v\u00fdzkum dvoubun\u011b\u010dn\u00e9ho dvougonadotropn\u00edho modelu, farmakologie dvojit\u00fdch receptor\u016f<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Stimulace pouze Leydigov\u00fdch bun\u011bk, spou\u0161t\u011bn\u00ed ovulace (napodoben\u00ed LH vrcholu), v\u00fdzkum obnovy HPG suprese specifick\u00e9 pro Leydigovy bu\u0148ky, farmakologie LHCGR<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Polo\u010das v plazm\u011b<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FSH ~30\u201340 h; LH-ekvivalentn\u00ed aktivita dominov\u00e1na spole\u010dn\u011b purifikovan\u00fdm HCG (33\u201337 h)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">33\u201337 h (termin\u00e1ln\u00ed f\u00e1ze)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typick\u00e1 v\u00fdzkumn\u00e1 d\u00e1vka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75\u2013225 IU SC (1\u20133 lahvi\u010dky) na pod\u00e1n\u00ed; 3\u00d7 t\u00fddn\u011b u chronick\u00fdch protokol\u016f<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">500\u20135 000 IU SC \/ IM (jednor\u00e1zov\u00e1 d\u00e1vka); 250\u2013500 IU\/den u chronick\u00fdch protokol\u016f<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>D\u00e1vkovac\u00ed jednotka v lahvi\u010dce<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75 IU biologick\u00e9 aktivity (mezin\u00e1rodn\u00ed referen\u010dn\u00ed d\u00e1vka)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5 000 nebo 10 000 IU biologick\u00e9 aktivity<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Status WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Zak\u00e1z\u00e1no za v\u0161ech okolnost\u00ed u mu\u017esk\u00fdch sportovc\u016f (S2 \u2014 Peptidov\u00e9 hormony)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Zak\u00e1z\u00e1no za v\u0161ech okolnost\u00ed u mu\u017esk\u00fdch sportovc\u016f (S2 \u2014 Peptidov\u00e9 hormony); v\u00fdjimka pro sportovkyn\u011b<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Pro v\u00fdzkum zam\u011b\u0159en\u00fd na dvoj\u00ed aktivaci LHCGR + FSHR, indukci spermatogeneze nebo kanonick\u00fd model dvou bun\u011bk a dvou gonadotropin\u016f je hMG standardn\u00ed referen\u010dn\u00ed slou\u010denina. Pro v\u00fdzkum zam\u011b\u0159en\u00fd pouze na stimulaci Leydigov\u00fdch bun\u011bk, spou\u0161t\u011bn\u00ed ovulace nebo specifickou farmakologii LHCGR HCG, <a href=\"https:\/\/medsbase.com\/cs\/hcg-peptide\/\">HCG<\/a> c\u00edlen\u011bj\u0161\u00edm n\u00e1strojem. Viz tak\u00e9 <a href=\"https:\/\/medsbase.com\/cs\/kisspeptin-10\/\">Kisspeptin-10<\/a> pro v\u00fdzkum hypotalamick\u00e9 pulzatility Kiss1R\/GnRH.<\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Pot\u0159ebujete BAC vodu?<\/strong> Rekonstituce jak\u00e9hokoli lyofilizovan\u00e9ho vialu vy\u017eaduje steriln\u00ed bakteriostatickou vodu. Sp\u00e1rujte tento produkt s na\u0161\u00edm <a href=\"\/cs\/bac-water\/\"><strong>BAC Water (Bakteriostatick\u00e1 voda)<\/strong><\/a> \u2014 30 mL multid\u00e1vkov\u00fdm vialem, 0,9% benzylalkoholem konzervovan\u00fdm, USP-grade.<\/div>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p><strong>P\u0159ed rekonstituci:<\/strong> lyofilizovan\u00e9 lahvi\u010dky skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C v p\u016fvodn\u00edm obalu pro kr\u00e1tkodob\u00e9 pracovn\u00ed z\u00e1soby. Pro dlouhodob\u00e9 skladov\u00e1n\u00ed zmrazte neotev\u0159en\u00e9 lahvi\u010dky p\u0159i \u221220 \u00b0C (stabilita \u226536 m\u011bs\u00edc\u016f p\u0159i \u221220 \u00b0C; \u226518 m\u011bs\u00edc\u016f p\u0159i 2\u20138 \u00b0C). Lyofilizovan\u00fd pr\u00e1\u0161ek je stabilizov\u00e1n manitolem nebo lakt\u00f3zou a je pom\u011brn\u011b odoln\u00fd v\u016f\u010di kr\u00e1tkodob\u00e9 expozici pokojov\u00e9 teplot\u011b b\u011bhem manipulace, ale m\u011bl by b\u00fdt co nejd\u0159\u00edve vr\u00e1cen do chladni\u010dky. Chra\u0148te p\u0159ed sv\u011btlem.<\/p>\n<p><strong>Postup rekonstituce:<\/strong> pro ka\u017edou lahvi\u010dku 75 IU vst\u0159\u00edkn\u011bte 1,0 ml bakteriostatick\u00e9 vody po bo\u010dn\u00ed st\u011bn\u011b lahvi\u010dky (ne p\u0159\u00edmo na lyofilizovan\u00fd pr\u00e1\u0161ek) \u2014 t\u00edm z\u00edsk\u00e1te pracovn\u00ed z\u00e1sobu 75 IU LH + 75 IU FSH na ml. Pro v\u00fdzkumn\u00e9 protokoly, kter\u00e9 vy\u017eaduj\u00ed vy\u0161\u0161\u00ed koncentrace (kombinace v\u00edce lahvi\u010dek pro vy\u0161\u0161\u00ed jednor\u00e1zovou d\u00e1vku), rekonstituujte 2\u20133 lahvi\u010dky se stejn\u00fdm celkov\u00fdm mno\u017estv\u00edm 1,0 ml rozpou\u0161t\u011bdla, abyste z\u00edskali 150\u2013225 IU\/ml. <strong>Jemn\u011b zakru\u017ete k rozpu\u0161t\u011bn\u00ed \u2014 net\u0159epejte, nepou\u017e\u00edvejte vortex.<\/strong> M\u00edch\u00e1n\u00ed s vysok\u00fdm smykov\u00fdm nap\u011bt\u00edm disociuje heterodimery \u03b1\/\u03b2 obou slo\u017eek LH a FSH a ni\u010d\u00ed bioaktivitu gonadotropinov\u00fdch receptor\u016f. Lyofilizovan\u00fd kol\u00e1\u010d na b\u00e1zi manitolu se obvykle rozpust\u00ed b\u011bhem 30\u201360 sekund p\u0159i jemn\u00e9m krou\u017een\u00ed.<\/p>\n<p><strong>Kritick\u00e1 pravidla skladov\u00e1n\u00ed rekonstituovan\u00e9ho materi\u00e1lu:<\/strong> po rekonstituci skladujte p\u0159i 2\u20138 \u00b0C a pou\u017eijte do 30 dn\u016f. <strong>Nezamrazujte rekonstituovan\u00e9 hMG<\/strong> \u2014 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed zp\u016fsobuj\u00ed disociaci LH a FSH \u03b1\/\u03b2 heterodimer\u016f (stejn\u00e9 fyzik\u00e1ln\u011b-chemick\u00e9 omezen\u00ed jako u HCG) a nevratn\u011b ni\u010d\u00ed biologickou aktivitu. Chra\u0148te p\u0159ed sv\u011btlem. Zlikvidujte, pokud se objev\u00ed z\u00e1kal, \u010d\u00e1stice nebo v\u00fdrazn\u00e1 zm\u011bna barvy. U v\u00fdzkumn\u00fdch protokol\u016f vy\u017eaduj\u00edc\u00edch v\u00edce aliquot p\u0159ipravte aliquoty v dob\u011b rekonstituce a skladujte p\u0159i 2\u20138 \u00b0C odd\u011blen\u011b nam\u00edsto zmrazov\u00e1n\u00ed.<\/p>\n<h2>\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>Jak\u00fd je rozd\u00edl mezi HMG a HCG?<\/h3>\n<p><a href=\"https:\/\/medsbase.com\/cs\/hcg-peptide\/\">HCG<\/a> je \u010dist\u00fd agonista LH\/CG receptoru \u2014 jedin\u00fd glykoproteinov\u00fd hormon (CAS 9002-61-3), kter\u00fd se v\u00e1\u017ee a aktivuje pouze LHCGR na Leydigov\u00fdch \/ thek\u00e1ln\u00edch \/ granul\u00f3zn\u00edch \/ lute\u00e1ln\u00edch bu\u0148k\u00e1ch. hMG je 1:1 sm\u011bs\u00ed LH a FSH biologick\u00e9 aktivity \u2014 odli\u0161n\u00e9 glykoproteinov\u00e9 hormony (kombinovan\u00e9 CAS 61489-71-2), kter\u00e9 se v\u00e1\u017eou jak na LHCGR (LH strana), tak na FSHR (FSH strana). Klinick\u00fdm a v\u00fdzkumn\u00fdm d\u016fsledkem je, \u017ee hMG vytv\u00e1\u0159\u00ed dvojitou receptorovou stimulaci, kter\u00e1 zapojuje ob\u011b poloviny dvoubun\u011b\u010dn\u00e9ho dvougonadotropinov\u00e9ho modelu (Leydigovy + Sertoliho bu\u0148ky u mu\u017e\u016f; thek\u00e1ln\u00ed + granul\u00f3zn\u00ed bu\u0148ky u \u017een), zat\u00edmco HCG vytv\u00e1\u0159\u00ed pouze jednoduchou receptorovou stimulaci strany LHCGR.<\/p>\n<h3>Co je to HCG kopurifikace v hMG a pro\u010d je d\u016fle\u017eit\u00e1 pro v\u00fdzkum?<\/h3>\n<p>Publikovan\u00e9 anal\u00fdzy slo\u017een\u00ed mo\u010dov\u00fdch p\u0159\u00edpravk\u016f hMG uv\u00e1d\u011bj\u00ed, \u017ee p\u0159ibli\u017en\u011b <strong>95% in-vivo LH-receptorov\u00e9 biologick\u00e9 aktivity<\/strong> je ve skute\u010dnosti zp\u016fsobeno stopov\u00fdm mno\u017estv\u00edm HCG kopurifikovan\u00e9ho z postmenopauz\u00e1ln\u00ed mo\u010di, nikoli samotn\u00fdm LH (Wolfenson et al., 2005). Je to proto, \u017ee HCG a LH se v\u00e1\u017eou na stejn\u00fd LHCGR s podobnou afinitou, ale HCG m\u00e1 polo\u010das v plazm\u011b 33\u201337 h oproti ~20 minut\u00e1m u LH \u2014 tak\u017ee i mal\u00e1 mno\u017estv\u00ed kopurifikovan\u00e9ho HCG dominuj\u00ed kumulativn\u00edmu in-vivo LH-ekvivalentn\u00edmu sign\u00e1lu. Pro v\u00fdzkumn\u00e9 protokoly, kde tento rozd\u00edl z\u00e1le\u017e\u00ed (nap\u0159. p\u0159i srovn\u00e1v\u00e1n\u00ed \u010dist\u00e9 LH farmakologie vs. HCG kontaminovan\u00e9ho sm\u00ed\u0161en\u00e9ho LH sign\u00e1lu), <strong>rekombinantn\u00ed LH (Luveris)<\/strong> je \u010dist\u0161\u00ed n\u00e1stroj. Pro protokoly, kde je c\u00edlem dvojit\u00e1 aktivace LHCGR + FSHR v pevn\u00e9m pom\u011bru 1:1, je hMG kanonickou referenc\u00ed.<\/p>\n<h3>Pro\u010d se hMG z\u00edsk\u00e1v\u00e1 z mo\u010di postmenopauz\u00e1ln\u00edch \u017een?<\/h3>\n<p>U \u017een po menopauze doch\u00e1z\u00ed ke ztr\u00e1t\u011b ovari\u00e1ln\u00ed negativn\u00ed zp\u011btn\u00e9 vazby hypothalamo-hypofyz\u00e1rn\u00ed osy, co\u017e dramaticky zvy\u0161uje sekreci LH a FSH z hypof\u00fdzy \u2013 typick\u00e9 hodnoty LH a FSH v s\u00e9ru po menopauze jsou 50\u2013100+ mIU\/ml pro ka\u017ed\u00fd hormon, co\u017e je \u0159\u00e1dov\u011b v\u00edce ne\u017e p\u0159ed menopauzou. Oba hormony jsou n\u00e1sledn\u011b ledvinami vylu\u010dov\u00e1ny do mo\u010di v koncentrovan\u00e9 form\u011b. Sdru\u017een\u00e1 mo\u010d \u017een po menopauze je proto nejkoncentrovan\u011bj\u0161\u00edm p\u0159\u00edrodn\u00edm zdrojem LH + FSH pro pr\u016fmyslovou extrakci. Pr\u016fmysl hMG byl postaven na tomto poznatku v po\u010d\u00e1tc\u00edch 60. let (Pergonal byl p\u016fvodn\u00ed p\u0159\u00edpravek spole\u010dnosti Serono) a pokra\u010duje dodnes, a\u010dkoli velk\u00e1 \u010d\u00e1st klinick\u00e9ho trhu p\u0159e\u0161la na rekombinantn\u00ed p\u0159\u00edpravky s \u010dist\u00fdm LH a \u010dist\u00fdm FSH.<\/p>\n<h3>Jak\u00e9 d\u00e1vkov\u00e9 rozsahy byly pou\u017eity ve v\u00fdzkumu?<\/h3>\n<p>Pou\u017eit\u00ed v jednor\u00e1zov\u00fdch v\u00fdzkumn\u00fdch protokolech obvykle zahrnuje 75\u2013225 IU podko\u017en\u011b na jednu aplikaci (1\u20133 lahvi\u010dky o s\u00edle 75 IU), s d\u00e1vkov\u00e1n\u00edm 3\u00d7 t\u00fddn\u011b nebo denn\u011b u chronick\u00fdch protokol\u016f. Protokoly pro indukci spermatogeneze v publikovan\u00fdch v\u00fdzkumech hypogonadotropn\u00edho hypogonadismu obvykle pou\u017e\u00edvaj\u00ed 75\u2013150 IU 3\u00d7 t\u00fddn\u011b po dobu 6\u201324 m\u011bs\u00edc\u016f v kombinaci s HCG (HCG poskytuje dodate\u010dnou stimulaci Leydigov\u00fdch bun\u011bk). Protokoly pro kultivaci Sertoliho bun\u011bk nebo granul\u00f3zn\u00edch bun\u011bk in vitro obvykle pou\u017e\u00edvaj\u00ed 1\u201310 IU\/ml v r\u016fstov\u00e9m m\u00e9diu. V\u00fdzkumn\u00edci by m\u011bli konzultovat prim\u00e1rn\u00ed literaturu vhodnou pro dan\u00fd druh, model a c\u00edl v\u00fdzkumu.<\/p>\n<h3>Jak\u00fd je rozd\u00edl mezi hMG a \u010dist\u00fdm rekombinantn\u00edm FSH (Gonal-F \/ Puregon)?<\/h3>\n<p>\u010cist\u00fd rekombinantn\u00ed FSH (follitropin alfa \/ Gonal-F; follitropin beta \/ Puregon; produkov\u00e1n v CHO bu\u0148k\u00e1ch z klonovan\u00fdch cDNA FSH \u03b1 a \u03b2) obsahuje <em>pouze<\/em> biologickou aktivitu FSH \u2013 \u017e\u00e1dn\u00e9 LH, \u017e\u00e1dn\u00e9 HCG. hMG obsahuje biologickou aktivitu jak LH, tak FSH v pom\u011bru 1:1 (plus stopov\u00e9 mno\u017estv\u00ed HCG). Pro v\u00fdzkumn\u00e9 protokoly, kter\u00e9 pot\u0159ebuj\u00ed \u010distou aktivaci FSHR izolovanou od signalizace LHCGR, je rekombinantn\u00ed FSH spr\u00e1vn\u00fdm n\u00e1strojem. Pro protokoly, kter\u00e9 pot\u0159ebuj\u00ed kombinovanou aktivaci obou receptor\u016f ve fyziologick\u00e9m pom\u011bru, je spr\u00e1vn\u00fdm n\u00e1strojem hMG. Publikovan\u00e9 p\u0159\u00edm\u00e9 srovn\u00e1vac\u00ed studie ve v\u00fdzkumu ovari\u00e1ln\u00ed stimulace porovn\u00e1valy ob\u011b l\u00e1tky s obecn\u011b srovnateln\u00fdmi v\u00fdsledky ve v\u00fdvoji folikul\u016f, ale s jemn\u011b odli\u0161n\u00fdmi profily odezvy na estradiol (hMG m\u00e1 tendenci produkovat m\u00edrn\u011b vy\u0161\u0161\u00ed hladiny estradiolu v polovin\u011b cyklu d\u00edky substr\u00e1tu androgen\u016f z LH strany, kter\u00fd poskytuje pro aromat\u00e1zu granul\u00f3zn\u00edch bun\u011bk).<\/p>\n<h3>Pro\u010d nelze rekonstituovan\u00e9 hMG zmrazit?<\/h3>\n<p>Stejn\u00fd d\u016fvod jako u HCG \u2013 jak LH, tak FSH jsou heterodimery dvou nekovalentn\u011b asociovan\u00fdch podjednotek (\u03b1 + \u03b2 ka\u017ed\u00fd). Interakce \u03b1\/\u03b2 je stabiln\u00ed v lyofilizovan\u00e9m pr\u00e1\u0161ku (\u017e\u00e1dn\u00e1 voda, kter\u00e1 by naru\u0161ila interakci) a stabiln\u00ed v chlazen\u00e9m vodn\u00e9m roztoku p\u0159i 2\u20138 \u00b0C (kinetika disociace je p\u0159i n\u00edzk\u00e9 teplot\u011b pomal\u00e1). Ale tvorba ledov\u00fdch krystal\u016f b\u011bhem zmrazov\u00e1n\u00ed fyzicky odd\u011bluje podjednotky a po rozmrazen\u00ed se znovu spojuj\u00ed pouze neefektivn\u011b. V\u00fdsledkem je, \u017ee zmra\u017een\u00e9 a rozmrazen\u00e9 hMG si zachov\u00e1v\u00e1 velk\u00fd pod\u00edl imunoreaktivity, ale ztr\u00e1c\u00ed velk\u00fd pod\u00edl biologick\u00e9 aktivity. Lyofilizovan\u00e9 hMG lze zmrazit a je stabiln\u00ed p\u0159i \u221220 \u00b0C; rekonstituovan\u00e9 hMG nelze.<\/p>\n<h3>Jak\u00fd je regula\u010dn\u00ed status hMG podle WADA?<\/h3>\n<p>hMG \/ menotropin je na Seznamu zak\u00e1zan\u00fdch l\u00e1tek Sv\u011btov\u00e9 antidopingov\u00e9 agentury (WADA) v t\u0159\u00edd\u011b S2 (Peptidov\u00e9 hormony, r\u016fstov\u00e9 faktory, p\u0159\u00edbuzn\u00e9 l\u00e1tky a mimika). Je zak\u00e1z\u00e1n v\u017edy \u2013 jak v sout\u011b\u017ei, tak mimo sout\u011b\u017e \u2013 pro mu\u017esk\u00e9 sportovce. V\u00fdzkumn\u00edci prov\u00e1d\u011bj\u00edc\u00ed v\u00fdzkum s hMG na lidsk\u00fdch subjektech mus\u00ed b\u00fdt v\u011bdomi tohoto regula\u010dn\u00edho statusu. Pro laboratorn\u00ed v\u00fdzkum in vitro a v\u00fdzkum na hlodavc\u00edch in vivo je status WADA pouze informativn\u00ed.<\/p>\n<h3>Jak se toto v\u00fdzkumn\u00e9 hMG srovn\u00e1v\u00e1 s zna\u010dkov\u00fdmi klinick\u00fdmi p\u0159\u00edpravky (Menopur, Menogon, Repronex)?<\/h3>\n<p>Klinick\u00e9 p\u0159\u00edpravky zna\u010dkov\u00fdch v\u00fdrobc\u016f jsou mo\u010dov\u011b extrahovan\u00e9 menotropiny (Menopur, Menogon, Repronex; historick\u00fd p\u0159\u00edpravek Pergonal byl ji\u017e v\u011bt\u0161inou sta\u017een z trhu) balen\u00e9 pod r\u016fzn\u00fdmi v\u00fdrobn\u00edmi SKU pro klinick\u00e9 pou\u017eit\u00ed v asistovan\u00e9 reprodukci. V\u00fdzkumn\u00fd hMG dod\u00e1van\u00fd zde je stejn\u00fd mo\u010dov\u011b extrahovan\u00fd p\u0159\u00edpravek s \u010distotou \u226599% HPLC, dod\u00e1van\u00fd bez ozna\u010den\u00ed pro klinick\u00e9 pou\u017eit\u00ed a ur\u010den\u00fd v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum. V\u00fdzkumn\u00edci hledaj\u00edc\u00ed menotropin pro klinick\u00e9 pou\u017eit\u00ed by jej m\u011bli z\u00edskat prost\u0159ednictv\u00edm klinick\u00e9ho dodavatelsk\u00e9ho \u0159et\u011bzce; v\u00fdzkumn\u00edci hledaj\u00edc\u00ed v\u00fdzkumn\u00fd materi\u00e1l pro in-vitro farmakologii receptor\u016f, in-vivo pr\u00e1ci na hlodavc\u00edch nebo jin\u00e9 laboratorn\u00ed aplikace mohou pou\u017e\u00edt materi\u00e1l dod\u00e1van\u00fd zde.<\/p>\n<h3>Lze hMG kombinovat s HCG, Kisspeptin-10 nebo testosteronem ve v\u00fdzkumn\u00fdch protokolech?<\/h3>\n<p>Ano \u2014 tyto slou\u010deniny c\u00edl\u00ed na r\u016fzn\u00e9 \u00farovn\u011b HPG osy a b\u011b\u017en\u011b se kombinuj\u00ed v publikovan\u00fdch v\u00fdzkumech. Nej\u010dast\u011bji publikovan\u00e9 kombinace jsou hMG + HCG (standardn\u00ed klinick\u00fd a v\u00fdzkumn\u00fd protokol pro indukci spermatogeneze u model\u016f hypogonadotropn\u00edho hypogonadismu \u2014 hMG poskytuje podporu na stran\u011b FSH, dodate\u010dn\u00e9 HCG poskytuje dopl\u0148kovou stimulaci na stran\u011b LH); hMG + <a href=\"https:\/\/medsbase.com\/cs\/kisspeptin-10\/\">Kisspeptin-10<\/a> (dissekce upstream + downstream \u2014 kisspeptin stimuluje endogenn\u00ed GnRH, zat\u00edmco hMG poskytuje p\u0159\u00edmou gonad\u00e1ln\u00ed stimulaci); hMG + exogenn\u00ed testosteron (pro v\u00fdzkum obnovy po supresi HPG, kde testosteron potla\u010duje endogenn\u00ed LH\/FSH a hMG obch\u00e1z\u00ed supresi p\u0159\u00edm\u00fdm p\u016fsoben\u00edm na gon\u00e1dy). Ka\u017edou slo\u017eku rekonstituujte zvl\u00e1\u0161\u0165 a dodr\u017eujte specifick\u00e1 pravidla skladov\u00e1n\u00ed \u2014 ani hMG, ani HCG by nem\u011bly b\u00fdt zmra\u017eeny po rekonstituci.<\/p>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 20px 0 8px; border-radius: 4px; font-size: 14px;\"><strong>Pro\u010d objedn\u00e1vat v\u00fdzkumn\u00e9 slou\u010deniny od MedsBase:<\/strong> Lyofilizovan\u00e9 peptidy a slou\u010deniny HPLC \u226599% \u00b7 COA dostupn\u00e9 na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava \u00b7 <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance<\/a> na ka\u017edou objedn\u00e1vku \u00b7 1,400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed v\u00fdzkumn\u00e9 peptidy pro HPG osu a reproduk\u010dn\u00ed v\u00fdzkum<\/h2>\n<ul>\n<li><a href=\"\/cs\/hcg-peptide\/\"><strong>HCG (lidsk\u00fd choriov\u00fd gonadotropin)<\/strong><\/a> \u2014 \u010cist\u00fd agonista receptoru LH\/CG \u2014 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed; pouze aktivita na stran\u011b LH<\/li>\n<li><a href=\"\/cs\/kisspeptin-10\/\"><strong>Kisspeptin-10<\/strong><\/a> \u2014 Agonista Kiss1R hypotalamu \u2014 upstream regul\u00e1tor HPG osy, \u0159\u00edd\u00ed pulzn\u00ed sekreci GnRH<\/li>\n<li><a href=\"\/cs\/pt-141\/\"><strong>PT-141 (Bremelanotid)<\/strong><\/a> \u2014 Agonista receptoru melanokortinu-4 \u2014 v\u00fdzkum sexu\u00e1ln\u00edch funkc\u00ed<\/li>\n<li><a href=\"\/cs\/oxytocin-acetate\/\"><strong>Oxytocin Acetate<\/strong><\/a> \u2014 Nonapeptid zadn\u00edho laloku hypof\u00fdzy \u2014 v\u00fdzkum reprodukce a soci\u00e1ln\u00edch vazeb<\/li>\n<li><a href=\"\/cs\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 Analog GHRH \u2014 odli\u0161n\u00e1 endokrinn\u00ed osa, \u010dasto studov\u00e1n spole\u010dn\u011b<\/li>\n<li><a href=\"\/cs\/bac-water\/\"><strong>BAC Water (Bakteriostatick\u00e1 voda)<\/strong><\/a> \u2014 Nezbytn\u00e9 pro rekonstituci jak\u00e9hokoli lyofilizovan\u00e9ho vialu \u2014 steriln\u00ed \u0159edidlo s 0,9% konzervantem benzylalkoholu<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Dvojit\u00e1 p\u0159\u00edprava glykoproteinov\u00fdch hormon\u016f LH + FSH \u2014 biologick\u00fd pom\u011br aktivity 1:1 (75 IU ka\u017ed\u00fd)<br \/>\n\u2705 Klasick\u00fd agonista dvoj\u00edch gonadotropinov\u00fdch receptor\u016f LHCGR + FSHR<br \/>\n\u2705 Mo\u010dov\u00fd extrakt menotropinu z poolovan\u00e9 mo\u010di postmenopauz\u00e1ln\u00edch \u017een (CAS 61489-71-2)<br \/>\n\u2705 Dvoubun\u011b\u010dn\u00fd dvougonadotropinov\u00fd model \u2014 p\u016fsob\u00ed na Leydigovy+Sertoliho nebo thek\u00e1ln\u00ed+granul\u00f3zn\u00ed bu\u0148ky<br \/>\n\u2705 Standardn\u00ed n\u00e1stroj pro v\u00fdzkum indukce spermatogeneze &amp; ovari\u00e1ln\u00ed stimulace<\/p>\n<p><strong>HMG (v\u00fdzkumn\u00e1 kvalita)<\/strong> obsahuje mo\u010dov\u00fd extrakt Human Menopausal Gonadotropin (menotropin).<\/p>","protected":false},"featured_media":71453,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6490,6495,6492,6497,6498,6496,6493,6494],"class_list":{"0":"post-71441","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-gonadotropin","8":"product_tag-hmg","9":"product_tag-hpg-axis","10":"product_tag-human-menopausal-gonadotropin","11":"product_tag-lhcgr-fshr-agonist","12":"product_tag-menotropin","13":"product_tag-reproductive-research","14":"product_tag-research-peptide","16":"first","17":"instock","18":"shipping-taxable","19":"purchasable","20":"product-type-variable","21":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/71441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=71441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/71453"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=71441"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=71441"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=71441"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=71441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}